Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-11-08 Call Transcript
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a short communication dated November 8, 2023, addressed to stock exchanges regarding the availability of the audio recording of the company's earnings call held on the same day. It references the earnings call for the quarter and half year ended September 30, 2023. The document does not contain the transcript itself but informs that the recording is available on the company's website. Given the short length (2201 characters) and the nature of the content (announcement of availability of earnings call recording), this is not the earnings release or the call transcript itself but an announcement related to the earnings call. According to the classification rules, announcements about earnings calls or their recordings fall under Call Transcript (CT) if the transcript is provided, but here only the recording availability is announced. Since it is an announcement about the earnings call recording, the best fit is Call Transcript (CT) as it relates directly to the earnings call content. Confidence is high because the document explicitly mentions the earnings call and its recording availability, which aligns with the CT category.
2023-11-08 English
Copy of Newspaper Publication
Regulatory Filings
2023-11-08 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 7, 2023, announcing the unaudited financial results for the quarter and half year ended September 30, 2023. It contains key consolidated financial highlights such as revenues, gross profit, EBITDA, PAT, and EPS for Q2 FY24 compared to Q2 FY23. The document is titled as a 'Press Release' and provides a summary of financial performance with some commentary from the Chairman and Managing Director. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), but rather an initial announcement of quarterly financial results. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only.
2023-11-07 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation Q2FY24' and contains detailed financial data including revenue, EBITDA, PBT, PAT, margins, segmental performance, and balance sheet summaries for Q2 and H1 FY24. It is prepared for investors and includes forward-looking statements, company overview, and future outlook. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The content matches the characteristics of an Investor Presentation, which typically includes detailed financials, strategy, and market position information. There is no indication that this is a regulatory filing, earnings release (which is usually shorter and less detailed), or an annual/interim report. Therefore, the correct classification is Investor Presentation (IP).
2023-11-07 English
Financial Result Updates
Regulatory Filings
2023-11-07 English
Outcome of Board Meeting
Regulatory Filings
2023-11-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.